Journal
JOURNAL OF CLINICAL IMMUNOLOGY
Volume 42, Issue 6, Pages 1193-1204Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-022-01273-x
Keywords
JAK-STAT pathway; DN STAT3; STAT1 GOF; ruxolitinib
Categories
Funding
- Job Research Foundation (NY, United States)
- Consejeria de Salud de la Junta de Andalucia [SA0051/2020]
- Agencia de Innovacion y Desarrollo de Andalucia [PI-0184-2018]
- Instituto de Salud Carlos III, Madrid, Spain [CD20/00124, JR18/00042, FIS PI19/01471]
Ask authors/readers for more resources
Ex vivo treatment with the JAK1/2 inhibitor ruxolitinib reduces cytokine responsiveness and normalizes STAT1 phosphorylation in DN STAT3 and STAT1 GOF patient's cells.
Purpose STAT1 gain-of-function (GOF) and dominant-negative (DN) STAT3 syndromes share clinical manifestations including infectious and inflammatory manifestations. Targeted treatment with Janus-kinase (JAK) inhibitors shows promising results in treating STAT1 GOF-associated symptoms while management of DN STAT3 patients has been largely supportive. We here assessed the impact of ruxolitinib on the JAK-STAT1/3 pathway in DN STAT3 patients' cells. Methods Using flow cytometry, immunoblot, qPCR, and ELISA techniques, we examined the levels of basal STAT1 and phosphorylated STAT1 (pSTAT1) of cells obtained from DN STAT3, STAT1 GOF patients, and healthy donors following stimulation with type I/II interferons (IFNs) or interleukin (IL)-6. We also describe the impact of ruxolitinib on cytokine-induced STAT1 signaling in these patients. Results DN STAT3 and STAT1 GOF resulted in a similar phenotype characterized by increased STAT1 and pSTAT1 levels in response to IFN alpha (CD3(+) cells) and IFN gamma (CD14(+) monocytes). STAT1-downstream gene expression and C-X-C motif chemokine 10 secretion were higher in most DN STAT3 patients upon stimulation compared to healthy controls. Ex vivo treatment with the JAK1/2-inhibitor ruxolitinib reduced cytokine responsiveness and normalized STAT1 phosphorylation in DN STAT3 and STAT1 GOF patient' cells. In addition, ex vivo treatment was effective in modulating STAT1 downstream signaling in DN STAT3 patients. Conclusion In the absence of effective targeted treatment options for AD-HIES at present, modulation of the JAK/STAT1 pathway with JAK inhibitors may be further explored particularly in those AD-HIES patients with autoimmune and/or autoinflammatory manifestations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available